Stromelysin inhibitors

US6337411B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Cordula Hopmann · Berlin, DE
• Martin Knauf · Frankfurt, DE
• Klaus-Ulrich Weithmann · Hofheim, DE
• Joachim Wink · Rödermark, DE

Key dates

• Filing date: Dec 15, 2000
• Grant date: Jan 8, 2002
• Expiry date: Dec 15, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of conditions whose course involves an increased activity of matrix-degrading enzymes, in particular stromelysin.